Alterations in inflammatory biomarkers and energy intake in cancer cachexia: a prospective study in patients with inoperable pancreatic cancer
- 786 Downloads
Chronic systemic inflammatory response is proposed as an underlying mechanism for development of cancer cachexia. We conducted a prospective study to examine changes in inflammatory biomarkers during the disease course and the relationship between inflammatory biomarkers and cachexia in patients with inoperable pancreatic cancer. Twenty patients, median (range) age 67.5 (35–79) years, 5 females, were followed for median 5.5 (1–12) months. Cachexia was diagnosed according to the 2011 consensus-based classification system (weight loss >5 % past six months, BMI < 20 kg/m2 and weight loss >2 %, or sarcopenia) and the modified Glasgow Prognostic score (mGPS) that combines CRP and albumin levels. Inflammatory biomarkers were measured by enzyme immunoassays. The patients had increased levels of most inflammatory biomarkers, albeit not all statistically significant, both at study entry and close to death, indicating ongoing inflammation. According to the consensus-based classification system, eleven (55 %) patients were classified as cachectic upon inclusion. They did not differ from non-cachectic patients with regard to inflammatory biomarkers or energy intake. According to the mGPS, seven (35 %) were defined as cachectic and had a higher IL-6 (p < 0.001) than the non-cachectic patients. They also had a slightly, but insignificantly longer survival than non-cachectic patients (p = 0.08). The mGPS should be considered as an additional framework for identification of cancer cachexia.
KeywordsAdvanced cancer Pancreatic cancer Cancer cachexia Inflammation Cytokines Adipokines
The entire data collection was carried out at the Departments of Surgery, Oncology and Palliative Care at Oslo University Hospital. Appreciation is expressed to the staff of the study and to patients who participated.
This study was funded by Oslo and Akershus University College of Applied Sciences and Hole’s trust fund.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Kneuertz PJ, Cunningham SC, Cameron JL, Torrez S, Tapazoglou N, Herman JM, et al. Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. J Gastrointest Surg. 2011;15(11):1917–27. doi: 10.1007/s11605-011-1665-9.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Laird BJ, Kaasa S, McMillan DC, Fallon MT, Hjermstad MJ, Fayers P, et al. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res. 2013;19(19):5456–64.CrossRefPubMedGoogle Scholar
- 18.Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15(8):2920–6. doi: 10.1158/1078-0432.CCR-08-2242.CrossRefPubMedGoogle Scholar
- 19.Wesseltoft-Rao N, Holven KB, Telle-Hansen VH, Narverud I, Iversen PO, Hjermstad MJ, et al. Measurements of body fat is associated with markers of inflammation, insulin resistance and lipid levels in both overweight and in lean, healthy subjects. e-SPEN Journal. 2012;7(6):e234–40. doi: 10.1016/j.clnme.2012.10.002.CrossRefGoogle Scholar
- 21.Blaker B, Aarsland M. Mål og vekt for matvarer. Oslo: Landsforeningen for Kosthold & Helse; 1989. p. 6–41.Google Scholar
- 22.Thomas B. Manual of dietetic practice. 2nd ed. Oxford: Blacwell; 1994.Google Scholar
- 23.van der Meij BS, Schoonbeek CP, Smit EF, Muscaritoli M, van Leeuwen PA, Langius JA. Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks. Br J Nutr. 2013;109(12):2231–9. doi: 10.1017/S0007114512004527.CrossRefPubMedGoogle Scholar
- 38.Dalamaga M, Migdalis I, Fargnoli JL, Papadavid E, Bloom E, Mitsiades N, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control. 2009;20(5):625–33. doi: 10.2307/40272028.CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Creutzberg EC, Wouters EFM, Vanderhoven-Augustin IML, Dentener MA, Schols AMWJ. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(4):1239–45. doi: 10.1164/ajrccm.162.4.9912016.CrossRefPubMedGoogle Scholar
- 44.Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care–correlations with food intake, metabolism, exercise capacity, and hormones. Cancer. 2005;103(10):2189–98. doi: 10.1002/cncr.21013.CrossRefPubMedGoogle Scholar
- 46.Vlachostergios PJ, Gioulbasanis I, Kamposioras K, Georgoulias P, Baracos VE, Ghosh S, et al. Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients. Oncology. 2011;81(2):113–8. doi: 10.1159/000331685.CrossRefPubMedGoogle Scholar